Gabapentin as a potential treatment for anxiety disorders.
Pollack
M H
MH
Matthews
J
J
Scott
E L
EL
D000085:Acetates / Q000627:therapeutic use*; D000328:Adult; D000525:Alprazolam / Q000627:therapeutic use; D000588:Amines; D000927:Anticonvulsants / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D003509:Cyclohexanecarboxylic Acids; D003975:Diazepam / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use; D000077206:Gabapentin; D006801:Humans; D008297:Male; D008875:Middle Aged; D016584:Panic Disorder / Q000188:drug therapy / Q000523:psychology; D010698:Phobic Disorders / Q000188:drug therapy / Q000523:psychology; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005473:Fluoxetine; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D003975:Diazepam; D000525:Alprazolam